TPTE2P1
Putative phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase TPTE2P1
Also known as: TPT2L_HUMAN
Protein identityUniProt · HPA
OverviewNCBI Gene
No narrative summary is available for TPTE2P1 in this catalog release; identity and structured annotations are shown without generated factual claims.
Canonical amino-acid sequenceUniProt
138 residues, UniProt reviewed canonical sequence.
>Q5T6R2|TPTE2P1
1 MPAAFPCVFP PQSLQVFPQM IVKVWEKQSL PLPGLRGSPV ERLYLPRNEL DNPHKQKAWK
61 IYPPEFAVEI LFGMVSVDSL LFVLSSPHWW LHLAQGSFWM SEGGFSLCHP GWSVVAQSLL
121 TSTSAFCVRA ILLPQPPELocalizationUniProt · AlphaFold · HPA
Whether an antibody against TPTE2P1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Unknown
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.41
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
Protein domainsUniProt · Pfam · InterPro
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads TPTE2P1 as an antibody target. Whether an autoantibody or antibody against TPTE2P1 could matter depends on whether native TPTE2P1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
TPTE2P1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label TPTE2P1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...